PYC Therapeutics Ltd
PYC
Company Profile
Business description
PYC Therapeutics Ltd is a clinical-stage biotechnology company creating a new generation of RNA therapies for patients with genetic diseases. The Group is engaged in drug development and progressing the Company's drug pipeline through preclinical and clinical development. The Company operates in a single business segment comprising the discovery and development of novel RNA therapeutics, with a single geographical location in Australia.
Contact
6 Verdun Street
Harry Perkins Institute of Medical Research
Nedlands
PerthWA6009
AUST: +61 861510992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
5
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
Our fair value is above the IPO range, but outcomes could differ widely.
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Several gaming shares are trading at a discount to our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.60 | 95.80 | -1.07% |
| CAC 40 | 8,144.83 | 2.00 | -0.02% |
| DAX 40 | 25,735.85 | 0.39 | -0.00% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,527.53 | 23.64 | -0.22% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 59,444.21 | 419.93 | 0.71% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,323.63 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,730.40 | 91.40 | -1.04% |
| SSE Composite Index | 3,577.62 | 10.21 | -0.28% |